A unique self-expanding stent to treat acute coronary syndrome (ACS) has received CE Mark approval for sale in the EU.

The Stentys platform is designed to ensure optimal apposition of a stent in the critical hours and days following an acute myocardial infarction (AMI) procedure. By maintaining continuous contact with the vessel's internal surface, the stent avoids being shifted out of place.

"For European regulatory approval, we have demonstrated how the Stentys stent perfectly conforms to a variable vessel anatomy after AMI stenting," said Gonzague Issenmann, CEO and co-founder of Stentys.

In December 2009, Stentys started enrolling patients in the randomised APPOSITION II clinical trial to compare the Stentys self-expanding stent against conventional stents in treating AMI patients.

Based in Princeton (USA) and Paris, Stentys is a cardiac device specialist that aims to extend successful stenting procedures to the treatment of complex blocked coronary arteries.